Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1878 1
1899 1
1930 1
1933 1
1934 1
1935 1
1936 2
1937 2
1938 2
1939 3
1940 3
1941 3
1942 2
1945 1
1946 13
1947 2
1948 20
1949 18
1950 11
1951 8
1952 22
1953 4
1954 11
1955 17
1956 6
1957 10
1958 12
1959 10
1960 9
1961 5
1962 12
1963 8
1964 7
1965 15
1966 13
1967 8
1968 11
1969 7
1970 9
1971 15
1972 10
1973 15
1974 6
1975 15
1976 8
1977 12
1978 4
1979 9
1980 10
1981 5
1982 7
1983 10
1984 11
1985 11
1986 7
1987 2
1988 6
1989 10
1990 5
1991 11
1992 4
1993 7
1994 6
1995 8
1996 7
1997 8
1998 6
1999 7
2000 8
2001 12
2002 16
2003 15
2004 13
2005 14
2006 13
2007 21
2008 12
2009 9
2010 14
2011 17
2012 13
2013 20
2014 25
2015 19
2016 12
2017 13
2018 18
2019 27
2020 25
2021 46
2022 41
2023 28
2024 35
2025 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

999 results

Results by year

Filters applied: . Clear all
Page 1
IMI Prevention of Myopia and Its Progression.
Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, Logan NS, Liu M, Morgan I, Ohno-Matsui K, Pärssinen O, Resnikoff S, Sankaridurg P, Saw SM, Smith EL 3rd, Tan DTH, Walline JJ, Wildsoet CF, Wu PC, Zhu X, Wolffsohn JS. Jonas JB, et al. Among authors: smith el 3rd. Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):6. doi: 10.1167/iovs.62.5.6. Invest Ophthalmol Vis Sci. 2021. PMID: 33909032 Free PMC article. Review.
Reply.
Smith EL. Smith EL. Orthopedics. 2021 Sep-Oct;44(5):262-263. doi: 10.3928/01477447-20210819-11. Epub 2021 Sep 1. Orthopedics. 2021. PMID: 34590951 Free article. No abstract available.
Myopia--yesterday, today, and tomorrow.
Mutti DO, Gwiazda J, Norton TT, Smith EL 3rd, Schaeffel F, To CH. Mutti DO, et al. Among authors: smith el 3rd. Optom Vis Sci. 2013 Nov;90(11):1161-4. doi: 10.1097/OPX.0000000000000117. Optom Vis Sci. 2013. PMID: 24152883 Free PMC article. No abstract available.
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy.
Baldacci S, Brea EJ, Facchinetti F, Li Z, Ngo K, Malhotra S, Booker MA, Tolstorukov MY, Chakravarti S, Hinchey C, Mahadevan NR, Lococo F, D'Agnelli S, Gnetti L, Campanini N, Leonetti A, Feng WW, Tsai JA, Hartley AV, Locquet MA, Fournel L, Alifano M, Mansuet-Lupo A, Saldanha A, Haller W, Zasadil LM, Zielinska M, Bui K, Tuladhar B, Lizotte PH, Ivanova EV, Sequist LV, Gokhale PC, Paweletz CP, Smith EL, Janne PA, Barbie DA. Baldacci S, et al. Among authors: smith el. Cancer Discov. 2025 Aug 6:10.1158/2159-8290.CD-24-1515. doi: 10.1158/2159-8290.CD-24-1515. Online ahead of print. Cancer Discov. 2025. PMID: 40762432 Free PMC article.
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.
Sklavenitis-Pistofidis R, Konishi Y, Heilpern-Mallory D, Wu T, Tsakmaklis N, Aranha MP, Hunter ZR, Ali AK, Tsuji J, Haradhvala NJ, Lightbody ED, Towle K, Hevenor L, Romee R, Briercheck EL, Smith EL, Liacos CI, Kastritis E, Dimopoulos MA, Treon SP, Getz G, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: smith el. Nat Commun. 2025 Feb 10;16(1):1480. doi: 10.1038/s41467-025-56323-w. Nat Commun. 2025. PMID: 39929803 Free PMC article.
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: smith el. J Clin Oncol. 2025 Feb 10;43(5):498-504. doi: 10.1200/JCO-24-01785. Epub 2024 Dec 4. J Clin Oncol. 2025. PMID: 39631041 Clinical Trial.
Novel Immunotherapies for Multiple Myeloma.
D'Agostino M, Boccadoro M, Smith EL. D'Agostino M, et al. Among authors: smith el. Curr Hematol Malig Rep. 2017 Aug;12(4):344-357. doi: 10.1007/s11899-017-0397-7. Curr Hematol Malig Rep. 2017. PMID: 28819882 Free PMC article. Review.
Integrative genomic identification of therapeutic targets for pancreatic cancer.
Guo JA, Gong D, Evans K, Takahashi K, Jambhale AD, Shiau C, Yu P, Wang S, Wu WW, Chugh S, Kapner KS, Dilly J, Zhao D, Chen P, Smith EL, Mancias JD, Vazquez F, Singh H, Hwang WL, Aguirre AJ. Guo JA, et al. Among authors: smith el. Cell Rep. 2025 Sep 23;44(9):116191. doi: 10.1016/j.celrep.2025.116191. Epub 2025 Aug 21. Cell Rep. 2025. PMID: 40848256 Free article.
Beyond BCMA: newer immune targets in myeloma.
Tan MSY, Chen Y, Smith EL. Tan MSY, et al. Among authors: smith el. Blood Adv. 2024 Aug 27;8(16):4433-4446. doi: 10.1182/bloodadvances.2023010856. Blood Adv. 2024. PMID: 38865708 Free PMC article. Review.
999 results